Cover of: Interferon in the Treatment of Neurological Disorders | Richard Alan Smith Read Online

Interferon in the Treatment of Neurological Disorders

  • 331 Want to read
  • ·
  • 88 Currently reading

Published by Marcel Dekker Inc .
Written in English


  • Therapeutic use,
  • Neuropsychopharmacology,
  • Health/Fitness,
  • Diseases,
  • Immunology,
  • Neurology & clinical neurophysiology,
  • Chemotherapy,
  • Interferon,
  • Nervous system

Book details:

The Physical Object
Number of Pages336
ID Numbers
Open LibraryOL8126201M
ISBN 100824779355
ISBN 109780824779351

Download Interferon in the Treatment of Neurological Disorders


Pariante CM, Orru MG, Baita A, et al. Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. Lancet. ; ()– by: This book provides a review of the latest findings in this field, giving the neurologist and non-neurologist the information they need to determine the best treatment. Neurological disorders covered include multiple sclerosis, stroke and epilepsy. Treatment of Neurological Disorders. This chapter provides an overview of available medical and selected nonmedical treatment options in neurological diseases. .   Certain cytokines such as interferon-α and interleukin-2 are often used in the treatment certain cancers and chronic diseases such as melanoma, hepatitis C infection and multiple sclerosis. Several neuropsychiatric side effects such as depression, anxiety, psychosis, suicidal ideation, hypomanic mood and cognitive impairment were reported in those patients Cited by:

  Treatment of Neurological Disorders with Intravenous Immunoglobulins. Edited by gerard said (Pp , £). Published by Martin Dunitz, London, ISBN 1 X. Over the past decade the introduction of high dose intravenous immunoglobulin (IvIg) therapy has transformed the treatment of some neuromuscular diseases, particularly multifocal motor Author: Michael Donaghy. An unpredictable disease of the central nervous system, multiple sclerosis (MS) can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted. Many investigators believe MS to be an autoimmune disease -- one in which the body, through its immune system, launches a defensive attack against its . The aim of this study is to analyze the application of interferon therapy in the treatment of MS-E: Process the disease, patients with multiple sclerosis who have passed the commission for.   The European Federation of Neurological Societies has been publishing management guidelines in the European Journal of Neurology for many years. Developed by a consensus approach, using graded evidence, and then fully peer reviewed, these guidelines provide gold-standard, best-practice guidance to the treatment of neurological disorders.

Diseases. Interferon beta-1a and interferon beta-1b are used to treat and control multiple sclerosis, an autoimmune treatment may help in reducing attacks in relapsing-remitting multiple sclerosis and slowing disease progression and activity in secondary progressive multiple sclerosis.. Interferon therapy is used (in combination with chemotherapy and InterPro: IPR   The board-certfied neurologists at The Neurological Associates of West Los Angeles aim to bring you the latest medical news in the diagnosis and treatment of neurological disorders and conditions such as multiple sclerosis. Please call us at () to schedule a .   Aim: Immunotherapy with interferon‐alfa (IFN‐alfa) is used in a variety of diseases in‐ and outside clinical trials (e.g. chronic hepatitis, melanoma, chronic myelogenous leukemia, renal cell carcinoma, multiple myeloma). Treatment with IFN‐alfa can cause (severe) neuropsychiatric side effects. The purpose of this article is to give an updated review of data Cited by: The invention concerns a method of preventing neurologic injury caused by hypersensitivity to interferons. The invention is useful to prevent progression of diseases such as Down Syndrome and Alzheimer's Disease. The method of the invention comprises the administration of a soluble antagonist of interferon. More particularly, the method concerns the in utero administration of a .